Innoviva, Inc. (NASDAQ:INVA) Stock Rated “Moderate Buy” by Wall Street Brokerages

Posted by George Bondi on Oct 10th, 2026

Shares of Innoviva, Inc. (NASDAQ:INVA – Get Free Report) have earned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $39.25.

A number of brokerages recently commented on INVA. Weiss Ratings downgraded shares of Innoviva from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, September 24th. Zacks Research upgraded Innoviva from a “strong sell” rating to a “hold” rating in a research report on Monday, August 31st. Oppenheimer assumed coverage on Innoviva in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $35.00 target price for the company. BTIG Research reissued a “buy” rating and issued a $42.00 price target on shares of Innoviva in a report on Monday, June 22nd. Finally, Cantor Fitzgerald reduced their price target on Innoviva from $36.00 to $34.00 and set an “overweight” rating for the company in a report on Friday, August 7th.

Get Our Latest Report on Innoviva

Institutional Investors Weigh In On Innoviva

A number of hedge funds and other institutional investors have recently bought and sold shares of INVA. BlackRock Inc. acquired a new position in shares of Innoviva during the 2nd quarter worth $77,562,000. Dimensional Fund Advisors LP lifted its stake in shares of Innoviva by 1.7% in the first quarter. Dimensional Fund Advisors LP now owns 4,436,427 shares of the biotechnology company’s stock valued at $103,366,000 after purchasing an additional 76,026 shares during the period. Bank of America Corp DE purchased a new stake in Innoviva during the second quarter worth about $37,873,000. Deutsche Bank AG acquired a new position in Innoviva during the second quarter worth about $20,847,000. Finally, William Blair Investment Management LLC purchased a new stake in shares of Innoviva during the 2nd quarter worth approximately $14,584,000. Institutional investors and hedge funds own 99.12% of the company’s stock.

Innoviva Stock Up 1.6%

Shares of NASDAQ:INVA opened at $21.21 on Friday. Innoviva has a fifty-two week low of $16.52 and a fifty-two week high of $25.15. The company has a quick ratio of 15.18, a current ratio of 16.01 and a debt-to-equity ratio of 0.21. The firm’s 50-day simple moving average is $20.96 and its 200-day simple moving average is $22.01. The company has a market cap of $1.53 billion, a price-to-earnings ratio of 5.17, a PEG ratio of 3.01 and a beta of 0.38.

About Innoviva

(Get Free Report)

Innoviva, Inc is a healthcare company focused on acquiring, developing and commercializing pharmaceutical assets, with a particular emphasis on medicines for respiratory and infectious diseases. The company generates a substantial portion of its business through royalty interests in marketed products and also invests in healthcare companies and development-stage therapies.

Innoviva holds royalty rights related to several respiratory medicines developed in collaboration with GlaxoSmithKline, including Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which is marketed as Relvar Ellipta in some international markets.